← Trials/Trial dossier/NCT07081178
WeGoReal
TerminatedA Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).
A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany Non-interventional.
Lead sponsor
Asset
Semaglutide
Subcutaneous · GLP-1 agonist
Listed sites
1
Recruiting sites
—
Enrollment
100
actual
Study population
Obesity / overweight
Key I/E criterion
—
Primary endpoint
•Body weight, % change
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Study population text
Two groups of participants are planned to be included, one Group (A) with those initiating semaglutide adjunct with lifestyle modification, and the other Group (B) with those only with lifestyle modification.
Eligibility criteria
Common inclusion criteria for Group A and Group B:
1. Male or female, age above or equal to 18 years at the time signing informed consent.
2. Body mass index (BMI) more than or equal to (≥) 30 kilogram per meter square (kg/m^2) with at least one of the following diagnosed obesity-related comorbidities:
arterial hypertension, pre-diabetes, Obstructive Sleep Apnea (OSA) or coronary heart disease, chronic heart failure, or BMI ≥35 kg/m^2.
3. History of at least one self-reported unsuccessful attempt to lose weight.
4. Capable of completing informed consent.
Additional inclusion criteria for Group A:
1. The decision to initiate treatment with commercially available Wegovy has been made by the participant and the treating physician before and independently from the decision to include the participant in this study.
2. Initiation of treatment is not modified in any case due to participant's participation in the study.
Common exclusion criteria for Group A and Group B:
1. Previous participation in this study (participation is defined as having given informed consent in this study)
2. Treatment with an investigational drug within 30 days prior to enrolment into the study.
3. Participant has had a prior serious allergic reaction to semaglutide or any of the ingredients in Wegovy.
4. Women with pregnancy or breast-feeding.
5. Women of childbearing potential and not using an adequate contraceptive method.
6. Men and women in their pregnancy attempts.
7. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
8. History of any Glucagon-like peptide-1 (GLP-1) treatment within 180 days.
9. History of type 1 or type 2 diabetes mellitus.
Endpoints (20)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
4 endpointsChange in relative body weight
Time frame:From baseline to month 6 and month 9
Body weight, % change
percent change from baseline, improvement
Change in relative body weight
Time frame:From baseline to month 3 and 12
Body weight, % change
percent change from baseline, improvement
Change in body weight
Time frame:from baseline to month 3, month 6, month 9 and month 12
Body weight, absolute change (kg)
change from baseline, improvement
Change in waist circumference
Time frame:from baseline to month 3, month 6, month 9 and month 12
Waist circumference, change
change from baseline, improvement
Glycemic / diabetes
2 endpointsChange in Haemoglobin A1c (HbA1c)
Time frame:from baseline to month 3, month 6, month 9 and month 12
HbA1c, change
change from baseline, improvement
LOINC 4548-4
Change in fasting plasma glucose (FPG)
Time frame:from baseline to month 3, month 6, month 9 and month 12
Fasting glucose, change
change from baseline, improvement
LOINC 1558-6
MASH / liver
3 endpointsChange in gamma-glutamyl transferase (GGT)
Time frame:from baseline to month 3, month 6, month 9 and month 12
γ-GT, change
change from baseline, improvement
Change in alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/GPT)
Time frame:from baseline to month 3, month 6, month 9 and month 12
ALT, change
change from baseline, improvement
LOINC 1742-6
Change in aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/GOT)
Time frame:from baseline to month 3, month 6, month 9 and month 12
AST, change
change from baseline, improvement
LOINC 1920-8
Renal / kidney
1 endpointChange in estimated glomerular filtration rate (eGFR) eGFR
Time frame:from baseline to month 3, month 6, month 9 and month 12
eGFR, change
change from baseline, improvement
LOINC 98979-8
Cardiometabolic biomarkers
9 endpointsChange in total cholesterol
Time frame:from baseline to month 3, month 6, month 9 and month 12
Total cholesterol, change
change from baseline, improvement
LOINC 2093-3
Change in high density lipoprotein (HDL)
Time frame:from baseline to month 3, month 6, month 9 and month 12
HDL-C, change
change from baseline, improvement
LOINC 2085-9
Change in low density lipoprotein (LDL)
Time frame:from baseline to month 3, month 6, month 9 and month 12
LDL-C, change
change from baseline, improvement
LOINC 13457-7
Change in very low density lipoprotein (VLDL)
Time frame:from baseline to month 3, month 6, month 9 and month 12
VLDL, change
change from baseline, improvement
Change in lipoprotein A [Lp(a)]
Time frame:from baseline to month 3, month 6, month 9 and month 12
change from baseline, improvement
Change in triglycerides
Time frame:from baseline to month 3, month 6, month 9 and month 12
Triglycerides, change
change from baseline, improvement
LOINC 2571-8
Change in systolic blood pressure (SBP)
Time frame:from baseline to month 3, month 6, month 9 and month 12
Systolic BP, change
change from baseline, improvement
LOINC 8480-6
Change in diastolic blood pressure (DBP)
Time frame:from baseline to month 3, month 6, month 9 and month 12
Diastolic BP, change
change from baseline, improvement
LOINC 8462-4
Change in C-reactive protein (CRP) or high-sensitivity C-reactive protein (hs-CRP)
Time frame:from baseline to month 3, month 6, month 9 and month 12
hs-CRP, change
change from baseline, improvement
LOINC 30522-7
Safety / tolerability / PK
1 endpointChange in platelet count
Time frame:from baseline to month 3, month 6, month 9 and month 12
change from baseline, descriptive
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.